# DESCRIPTION

## FIELD OF INVENTION

- define novel vaccine consortium

## BACKGROUND AND PRIOR ART OF THE INVENTION

- motivate enteric fever problem
- summarize current vaccine limitations
- highlight importance of OMVs
- emphasize need for cost-effective solution

## OBJECTIVES OF THE INVENTION

- outline primary objectives
- list additional objectives

## DETAILED DESCRIPTION OF THE INVENTION

- introduce novel formulation of isolated outer membrane vesicles
- describe composition of formulation
- discuss immunogenicity and protective efficacy
- compare with mutated strains
- highlight advantages over conventional methods
- describe preparation of OMVs
- discuss significance of Vi-polysaccharide in vaccine constituents

### Bacterial Strains and Culture Conditions

- describe bacterial strains and culture conditions

### Preparation of OMVs

- describe preparation of OMVs
- discuss characterization of isolated OMVs

### Negative Staining of OMVs and OMV-Secreting Bacteria

- describe negative staining of OMVs and OMV-secreting bacteria

### Animals

- describe animal model used for immunization

### Collection of Serum and Stool

- describe collection of serum and stool
- discuss processing of collected samples

### SDS-PAGE and Immunoblot

- describe SDS-PAGE and immunoblot analysis

### Dot Blot Assay.

- describe dot blot analysis

### ELISA

- describe ELISA method
- discuss measurement of different immunoglobulins
- describe coating of micro-titer wells
- discuss incubation and washing steps
- describe measurement of OD492

### Ex Vivo Studies on Isolated Dendritic Cells

- describe ex vivo studies on isolated dendritic cells
- discuss treatment of cells with bivalent OMV
- describe measurement of cytokines
- discuss splenocyte re-stimulation assay
- describe measurement of cytokines
- discuss significance of results
- describe motility assay
- discuss inhibition of motility
- describe immunization with bivalent OMVs
- discuss protection in adult mice model
- describe measurement of body weight
- discuss percent survival
- describe challenge with heterologous strains
- discuss systemic infection of bacteria
- describe colonization of spleen and liver
- discuss significance of results
- describe statistical analysis
- discuss significance of statistical analysis

## The Non-Limiting Advantages are Given Below:

- list advantages of consortium
- demonstrate immunogenicity
- show protection against salmonellae

